On October 15, 2020 Adaptimmune Therapeutics plc ("Adaptimmune") (Nasdaq: ADAP), reported a leader in cell therapy to treat cancer is aware of the early release of the abstract entitled "Initial safety, efficacy, and product attributes from the SURPASS trial with ADP-A2M4CD8, a SPEAR T-cell therapy incorporating an affinity optimized TCR targeting MAGE-A4 and a CD8α co-receptor" by the Society for the Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) ("SITC") Conference (Press release, Adaptimmune, OCT 15, 2020, View Source [SID1234568522]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The full abstract is attached to this release.

The Company will update on the full dose escalation cohort of the SURPASS trial (6 patients in total) at the virtual SITC (Free SITC Whitepaper) conference on November 11, 2020 at 9 AM EST when posters are made available online.